Anticlimax 发表于 2025-3-25 04:59:38

Submitted on: 02 November 2022.
Revised on: 04 January 2023.
Accepted on: 17 February 2023.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

construct 发表于 2025-3-25 08:15:39

http://reply.papertrans.cn/1/84/8344/8344-22.png

玩笑 发表于 2025-3-25 11:54:40

http://reply.papertrans.cn/1/84/8344/8344-23.png

syncope 发表于 2025-3-25 19:52:21

Submitted on: 17 February 2009.
Revised on: 03 May 2009.
Accepted on: 16 June 2009.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

同位素 发表于 2025-3-25 21:43:10

Submitted on: 22 December 2010.
Revised on: 08 February 2011.
Accepted on: 12 March 2011.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

态度暖昧 发表于 2025-3-26 01:38:29

http://reply.papertrans.cn/1/84/8344/8344-26.png

和音 发表于 2025-3-26 05:23:04

http://reply.papertrans.cn/1/84/8344/8344-27.png

CRASS 发表于 2025-3-26 08:48:05

http://reply.papertrans.cn/1/84/8344/8344-28.png

边缘 发表于 2025-3-26 15:51:27

Submitted on: 02 November 2022.
Revised on: 24 February 2023.
Accepted on: 19 April 2023.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

aquatic 发表于 2025-3-26 19:28:42

Submitted on: 22 March 2019.
Revised on: 16 July 2019.
Accepted on: 08 August 2019.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets
页: 1 2 [3] 4
查看完整版本: SCIE期刊Endocrine Metabolic & Immune Disorders-Drug Targets 2024/2025影响因子:2.108 (ENDOCR METAB IMMUNE) (1871-5303). (IMMUN